A functional assay for measuring activated thrombin-activatable fibrinolysis inhibitor in plasma

Analytical Biochemistry

Volumn 330, Issue 2, 2004, Pages 332-341

  Neill, Erin K T ^a   Stewart, Ronald J ^a   Schneider, Mark M ^a   Nesheim, Michael E ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; DEGRADATION;

COFACTOR ACTIVITY; CONCENTRATION-DEPENDENT; DEGRADATION PRODUCTS; FUNCTIONAL ASSAYS; HIGH MOLECULAR WEIGHT; INTER-ASSAY VARIABILITY; PHYSIOLOGIC FUNCTION; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR (TAFI);

ENZYMES;

CARBOXYPEPTIDASE; FIBRIN; LYSINE; PLASMIN; PLASMINOGEN; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOMODULIN;

ARTICLE; BLOOD ANALYSIS; BLOOD CLOT LYSIS; CARBOXY TERMINAL SEQUENCE; CONCENTRATION RESPONSE; HEMOSTASIS; HUMAN; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; SENSITIVITY AND SPECIFICITY;

EID: 2942525590     PISSN: 00032697     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ab.2004.04.007     Document Type: Article

References (20)

1. Bajzar L., Manuel R., Nesheim M.E. Purification and characterization of TAFI, a thrombin activatable fibrinolysis inhibitor. J. Biol. Chem. 270:1995;14477-14484
2. Bajzar L., Morser J., Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J. Biol. Chem. 271:1996;16603-16608
3. Mao S.S., Cooper C.M., Wood T., Shafer J.A., Gardell S.J. Characterization of plasmin-mediated activation of plasma procarboxypeptidase B. Modulation by glycosaminoglycans. J. Biol. Chem. 274:1999;35046-35052
4. Bajzar L. Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway. Arterioscler. Thromb. Vasc. Biol. 20:2000;2511-2518
5. Walker J.B., Hughes B., James I., Haddock P., Kluft C., Bajzar L. Stabilization versus inhibition of TAFIa by competitive inhibitors in vitro. J. Biol. Chem. 278:2003;8913-8921
6. Wang W., Boffa M.B., Bajzar L., Walker J.B., Nesheim M.E. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activatable fibrinolysis inhibitor. J. Biol. Chem. 273:1998;27176-27181
7. Bajzar L., Nesheim M.E., Tracy P.B. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood. 88:1996;2093-2100
8. Boffa M.B., Wang W., Bajzar L., Nesheim M.E. Plasma and recombinant thrombin-activatable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties. J. Biol. Chem. 273:1998;2127-2135
9. Schneider M., Boffa M., Stewart R., Rahman M., Koschinsky M., Nesheim M. Two naturally occurring variants of TAFI (Thr-325 and Il-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. J. Biol. Chem. 277:2002;1021-1030
10. Nesheim M. Fibrinolysis and the plasma carboxypeptidase. Curr. Opin. Hematol. 5:1998;309-313
11. Brouwers G.J., Vos H.L., Leebeek F.W.G., Bulk S., Schneider M., Boffa M., Koschinsky M., van Tilburg N.H., Nesheim M.E., Bertina R.M., García E.B.G. A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels. Blood. 98:2001;1992-1993
12. E.G. Erdos, in Bradykinin, Kallidin and Kallikrein; Handbook of Experimental Pharmacology (Erdos, E. G., Eds.), Springer-Verlag Berlin Heidelberg, New York, pp. 427-487
13. Bouma B.N., Mosnier L.O., Meijers J.C., Griffin J.H. Factor XI dependent and independent activation of thrombin activatable fibrinolysis inhibitor (TAFI) in plasma associated with clot formation. Thrombosis Haemostasis. 82:1999;1703-1708
14. Walker J.B., Nesheim M.E. A kinetic analysis of the tissue plasminogen activator and DSPAα1 cofactor activities of untreated and TAFIa-treated soluble fibrin degradation products of varying size. J. Biol. Chem. 276:2001;3138-3148
15. Schleuning W.D., Alagon A., Boidol W., Bringmann P., Petri T., Kratzschmar J., Haendler B., Langer G., Baldus B., Witt W., Donner P. Plasminogen activators from the saliva of Desmodus rotundus (Common Vampire Bat): unique fibrin specificity. Ann. NY Acad. Sci. 667:1992;395-403
16. Bringmann P., Gruber D., Liese A., Toschi L., Kratzschmar J., Schleuning W.D., Donner P. Structural features mediating fibrin selectivity of vampire bat plasminogen activators. J. Biol. Chem. 270:1995;25596-25603
17. Walker J.B., Nesheim M.E. The molecular weights, mass distribution, chain composition, and structure of soluble fibrin degradation products released from a fibrin clot perfused with plasmin. J. Biol. Chem. 274:1999;5201-5212
18. Horrevoets A.J.G., Pannekoek H., Nesheim M.E. Production and characterization of recombinant human plasminogen (S741C-Fluorescein): a novel approach to study zymogen activation without generation of active protease. J. Biol. Chem. 272:1997;2176-2182
19. Lijnen H.R. Elements of the fibrinolytic system. Ann. NY Acad. Sci. 936:2001;226-236
20. Redlitz A., Tan A.K., Eaton D.L., Plow E.F. Plasma carboxypeptidases as regulators of the plasminogen system. J. Biol. Chem. 96:1995;2534-2538